Home › Castration-Resistant Prostatic Cancer › Washington
Castration-Resistant Prostatic Cancer clinical trials in Washington
6 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Washington.
Cities in Washington
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutch Cancer Center Sloan Clinic 2, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- VA Puget Sound Healthcare System, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- University of Washington, Seattle
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Fred Hutchinson Cancer Center ( Site 0013), Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Investigational Site Number: 400, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.